When Dr. Ed Kaye was the CEO of Sarepta Therapeutics, he steered the company through a controversial approval process for its drug to treat Duchenne muscular dystrophy. The drug, Exondys 51, won approval based on a trial in only 12 patients, against the advice of a Food and Drug Administration panel and amid strong lobbying by families affected by Duchenne muscular dystrophy.
That decision in 2016 has helped shape FDA policy for rare diseases ever since. Kaye, who’d been Sarepta’s chief medical officer for six years before stepping into the CEO role for nine months, left the company in 2017.
Now he runs Stoke Therapeutics, a startup working on medicines for severe genetic diseases. Its goal is to develop drugs that target RNA splicing — the editing of RNA “messages” copied from our genes — so that more proteins are made in diseases where they are missing or diminished. Kaye talked with STAT recently about both Stoke and lessons learned from Sarepta.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
